(GIST OF SCIENCE REPORTER) Tirzepatide

(JULY-2024)

India is set to approve the weight-loss drug tirzepatide marking a significant advancement in obesity treatment.
This follows global trends where drugs like semaglutide (Ozempic and Wegovy) have shown dramatic weight loss effects.
Tirzepatide, originally approved for diabetes, also induces weight loss by boosting hormones GLP-1 and GIP, which promote satiety and manage glucose levels.
Clinical trials have demonstrated substantial weight loss with tirzepatide, with participants losing up to 20.9% of their body weight.
However, ongoing use is necessary to maintain these results, as stopping the medication leads to weight regain.
Side effects include nausea, vomiting, and risk of thyroid tumours.